LIVRAISON GRATUITE - SANS VALEUR MINIMALE - PAIEMENT SÉCURISÉ - GRANDE SÉLECTION - PETIT PRIX

Tu aimes ce produit? Fais passer!

Description

Type 2 diabetes mellitus is a progressive disease that affects almost 8.3% of global population. Regardless the availability of vast variety of oral hypoglycemics, only 36% of patients achieves proper glycemic control. With the advantage of low risk of hypoglycemia, DPP-IV attracted the attention of medicinal chemists as a new target for oral hypoglycemics. In this report, a lead compound 1, with antipyrine scaffold, was obtained, and its binding mode was calculated. Several derivatives with bridged nitrogenous heterocycles have been synthesized via multi-component reaction under controlled microwave heating conditions. The antidiabetic activity vs. DPP-IV protein was evaluated and compared with sitagliptin. Compounds with small or medium sized nitrogenous bridges were comparable with sitagliptin in term of DPP-IV inhibitory activity, potentially via targeting Glu203 and Glu204. The oral hypoglycemic activities of compounds with submicromolar IC50 values were further evaluated using diabetic mouse model.

Contributeurs

Auteur Mohamed Abdalla

Détails sur le produit

DUIN 15FB12420RV

GTIN 9783659800290

Date de publication 19.09.2017

Langues Anglais

Nombre de pages 60

Type de produit Livre de Poche

Dimension 220 x 150  mm

Novel 4-Heteroaryl-Antipyrines as DPP-IV Inhibitors

Mohamed Abdalla

35,39 €

Vendeur: Dodax EU

Date de livraison: entre jeudi, 30. août et lundi, 3. septembre

État: Neuf

TVA incluse - Livraison GRATUITE
1
Ajouter au panier Ajouter au panier
35,39 €
TVA incluse - Livraison GRATUITE